A clinical study to check whether metformin gel with a healing material made from ones own blood improves gum and bone healing in lower back teeth having bone loss between roots of teeth.

Clinico-radiographic assessment of 1 percent metformin gel with Advanced-platelet-rich fibrin in the treatment of mandibular grade 2 furcation defects - A Split-Mouth Clinical study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105576

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R938- Abnormal findings on diagnostic imaging of other specified body structures

Interventions

Intervention1: 1 percent Metformin gel in combination with Advanced platelet rich fibrin: Metformin has osteogenic, anti-inflammatory, and immunomodulatory properties and A-PRF has more porous fibrin

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patiets willing and able to provide informed consent. 2.Medically healthy patients with no systemic diseases. 3.Diagnosed with chronic periodontitis. 4.Patients capable of maintaining good oral hygiene. 5.Asymptomatic mandibular first and second molars exhibiting radiolucency in the furcation area on intraoral periapical radiographs (IOPA) bilaterally. 6.Presence of bilateral Grade 2 furcation defects in mandibular molars that are endodontically vital (as confirmed clinically and radiographically). 7.Patients with a minimum of 20 permanent teeth, including at least two teeth with Grade 2 furcation defects, horizontal probing depth (PD) more than 3 mm, interproximal Probing depth more than or equal to 5 mm, and clinical attachment loss more than or equal to 3 mm, evaluated 8 weeks after Phase I therapy (scaling and root planing).

Exclusion criteria

Exclusion criteria: 1.Hematological disorders or immunocompromised status. 2.Pregnant or lactating women. 3.Smokers or users of any form of tobacco. 4.Use of medications known to interfere with wound healing or bone metabolism. 5.History of systemic antibiotic therapy or periodontal treatment within the past 6 months. 6.Restorations extending beyond the cemento-enamel junction (CEJ) at the defect site. 7.Indistinguishable CEJ, either clinically or radiographically. 8.Presence of periapical pathology, unrestored caries, defective restorations, root resorption, or vertical root fracture. 9.Tooth mobility classified as Miller Class 2 or greater. 10.Unacceptable oral hygiene (Plaque Index more than 1.5) after re-evaluation of Phase I therapy. 11.Patients unwilling to provide informed consent. 12.Known allergy to metformin or history of its systemic use.

Design outcomes

Primary

Measure	Time frame
Effectiveness of 1 percent metformin gel and A-PRF under parameters of radiographic assessment of bone gain in furcation area and defect fillTimepoint: Every 3 months for 9 months	—

Secondary

Measure	Time frame
Effectiveness of 1 percent metformin gel and A-PRF under parameters like probing pocket depth, clinical attachment level, plaque index.Timepoint: Every 3 months for 9 months	—

Countries

India

Contacts

Public ContactDr Raju Anarthe

Pravara Institute of Medical Sciences

rajuanarthe@gmail.com9860925006

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026